Effect of ketorolac and dexamethasone injections on pain after renal stent surgery

Submission date	Recruitment status	[X] Prospectively registered
04/03/2024	No longer recruiting	[_] Protocol
Registration date	Overall study status	Statistical analysis plan
06/03/2024	Completed	[] Results
Last Edited 06/03/2024	Condition category Urological and Genital Diseases	Individual participant data
		[] Record updated in last year

Plain English summary of protocol

Background and study aims

Many patients suffer from kidney stone surgery particularly the insertion of a ureteral stent (a thin tube inserted into the ureter). After stent removal, a high percentage of patients experience substantial kidney pain. The aim of this study is to investigate whether the administration of ketorolac and dexamethasone during stent removal can decrease the level of kidney pain.

Who can participate?: Adult patients aged 18 to 85 years who undergo stent placement for kidney/ureteral stones

What does the study involve?:

Patients will be randomly placed into three study groups: the ketorolac group, which will receive an intramuscular injection (into a muscle) of ketorolac and an intramuscular injection of 0.9% normal saline within 30 minutes of stent removal, the ketorolac and dexamethasone group, which will receive an intramuscular injection of ketorolac and dexamethasone within 30 minutes of stent removal, and the placebo group, which will receive two intramuscular injections of 0.9% normal saline. All patients will be assessed 1 and 7 days after stent removal.

What are the possible benefits and risks of participating? The possible benefits are decreased level of kidney pain and fewer missed days of work after stent removal. The possible risks are injection site reactions and infections.

Where is the study run from? Erfain Hospital (Iran)

When is the study starting and how long is it expected to run for? December 2023 to April 2024

Who is funding the study? Investigator initiated and funded Who is the main contact? Dr Mohammadreza Noroozi, noroozi.mr@cfbcr.org

Contact information

Type(s) Public, Scientific, Principal Investigator

Contact name Prof Mohammadreza Noroozi

Contact details Shahid Riazi Bakhshayesh St. Saadat Abad Tehran Iran 1945784320 +98 (0)9122328891 noroozi.mr@cfbcr.org

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers CFBCR.REC.2023019

Study information

Scientific Title

Efficacy and safety of intramuscular ketorolac and dexamethasone for preventing renal colic post stent removal: a randomized triple-blind, placebo-controlled clinical trial

Study objectives Intramuscular ketorolac and dexamethasone alleviate renal pain after stent removal

Ethics approval required Ethics approval required

Ethics approval(s)

Approved 05/12/2023, Ethics Committee of Center for Fundamental, Biomedical and Clinical Research (Shahid Riazi Bakhshayesh St. Saadat Abad, Tehran, 1945784320, Iran; +98 (0) 2161323389; vcr@cfbcr.org), ref: CFBCR.REC.2023019

Study design Randomized triple-blind placebo-controlled clinical trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s)

Hospital

Study type(s) Safety, Efficacy

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Preventing renal colic post stent removal

Interventions

Patients will be randomized into three study groups (block randomization with a block size of 6): 1. Ketorolac group (K group), which will receive an intramuscular injection of ketorolac (ketorolac tromethamine, 30 mg in 1 ml) and an intramuscular injection of 1 ml of 0.9% normal saline within 30 minutes of stent removal

2. Ketorolac and dexamethasone group (KD group), which will receive an intramuscular injection of ketorolac (Ketorolac tromethamine, 30 mg in 1 ml) and dexamethasone (dexamethasone phosphate, 8 mg in 2 ml) within 30 minutes of stent removal

3. Placebo group (P group), which will receive two intramuscular injections of 1 ml of 0.9% normal saline.

A blinded, qualified nurse performed the injections. All patients will be assessed 1 and 7 days after stent removal.

Intervention Type Drug

Pharmaceutical study type(s) Not Applicable

Phase Phase II

Drug/device/biological/vaccine name(s)

Ketorolac tromethamine, dexamethasone phosphate

Primary outcome measure

Pain measured using the visual analogue score (VAS) on day 1 and day 7

Secondary outcome measures

1. Opioid use, measured by the number of patients with any opioid use on day 1

2. Urgent pain-related clinical encounters, measured by the number of pain-related clinical encounters in the emergency department since the stent removal

3. Subjective renal colic symptoms, measured by the number of patients that experienced renal colic symptoms since the stent removal to day 7

4. Missed days of work, measured by the number of missed days of work since the stent removal to day 7

5. Injection complications, measured as the number of patients with any injection complication since the stent removal to day 7

Overall study start date

01/12/2023

Completion date

30/04/2024

Eligibility

Key inclusion criteria

1. Patients who underwent stent placement for renal/ureteral stones and returned for cystoscopical stent removal 2. Age between 20 and 85 years old

3. Providing informed consent

Participant type(s) Patient

Age group Adult

Lower age limit 20 Years

Upper age limit 85 Years

Sex Both

Target number of participants

174

Key exclusion criteria

- 1. Absolute or relative contraindication to ketorolac or dexamethasone
- 2. Acute or chronic renal failure (estimated glomerular filtration rate <50)
- 3. History of GI bleeding or peptic ulcer disease

4. Elevated risk of bleeding including cerebrovascular bleeding, haemorrhagic diathesis, use of any anticoagulants, or any bleeding disorder

5. Systemic infections or cerebral malaria

6. Use of live or live-attenuated vaccines6. Concurrent use of NSAIDs or corticosteroids7. Pregnancy8. Breastfeeding

Date of first enrolment 15/03/2024

Date of final enrolment 29/04/2024

Locations

Countries of recruitment Iran

Study participating centre Erfain Hospital Shahid Riazi Bakhshayesh St. Saadat Abad Tehran Iran 1945784687

Sponsor information

Organisation Center for Fundamental Biomedical Clinical Research

Sponsor details Shahid Riazi Bakhshayesh St. Saadat Abad Tehran Iran 1945784320 +98 (0)2161323389 cfbcr@cfbcr.org

Sponsor type Research organisation

Funder(s)

Funder type Other **Funder Name** Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact journal

Intention to publish date 01/08/2024

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date